ATPIF1 Antibody [L4C2] | Primary Antibodies

Application: Reactivity: Mouse, Rat, Cow, Human

Usage Information

Dilution
WB1:2000 IF1:200 FCM1:2000

Application
WB, IF, FCM

Reactivity
Mouse, Rat, Cow, Human

Source
Mouse Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
12 kDa 12 kDa
^*Why do the predicted and actual molecular weights differ? The following reasons may explain differences between the predicted and actual protein molecular weight. Post-translational modifications(e.g., phosphorylation, glycosylation); Splice variants and isoforms; Relative charge; Multimerization.

Datasheet & SDS

Biological Description

Specificity
ATPIF1 Antibody [L4C2] detects endogenous levels of total ATPIF1 protein.

Clone
L4C2

Synonym(s)
ATPI, ATPIF1, ATP5IF1, ATP synthase F1 subunit epsilon, Inhibitor of F(1)F(o)-ATPase, IF(1), IF1

Background
ATPase inhibitory factor 1 (ATPIF1/IF1) is a mitochondrial inner-membrane protein conserved among eukaryotes that acts as the physiological inhibitor of the F1Fo‑ATP synthase, linking cellular energy status and respiratory chain activity to ATP preservation, mitochondrial membrane potential, and downstream signaling responses. The mature IF1 protein comprises an N‑terminal mitochondrial targeting sequence, a helical inhibitory region that interacts with the catalytic interface of the F1 sector, and a C‑terminal segment that supports oligomerization; its inhibitory activity is modulated by pH-dependent conformational changes and reversible oligomer formation, which alter its binding affinity for ATP synthase. During severe mitochondrial depolarization or loss of the proton motive force, IF1 binds to the F1 catalytic head, inhibiting the reverse, ATP-hydrolyzing action of ATP synthase, thereby preventing ATP depletion and contributing to the maintenance of a minimal mitochondrial membrane potential that supports cell survival during acute energy stress. IF1 also promotes assembly of ATP synthase dimers into oligomeric structures along mitochondrial cristae ridges, a configuration that lowers catalytic turnover, modifies proton flux, and preserves cristae ultrastructure, connecting IF1 to both the structural organization and the catalytic regulation of the oxidative phosphorylation machinery. Tissue-specific analyses reveal elevated IF1 levels in mitochondria-rich organs such as heart, liver, and brain, where its modulation of ATP synthase inhibition influences baseline oxidative phosphorylation rates, reactive oxygen species production, and the metabolic balance between oxidative phosphorylation and glycolysis. In cancer, IF1 is frequently overexpressed and is associated with a metabolic shift toward aerobic glycolysis: ATP synthase inhibition by IF1 reduces oxidative phosphorylation capacity, increases reliance on glycolytic ATP production, and activates retrograde signaling pathways based on changes in mitochondrial membrane potential and reactive oxygen species, supporting cell proliferation, survival under hypoxic or anoxic conditions, and, in certain contexts, an anti-metastatic phenotype. In the nervous system, IF1 expression and activity contribute to neuronal resilience, as experimental upregulation of IF1 protects dopaminergic neurons from mitochondrial toxins by restricting ATP hydrolysis, preserving mitochondrial integrity, and reducing apoptotic cell loss, indicating a neuroprotective function when respiratory chain integrity is compromised.

Background

ATPase inhibitory factor 1 (ATPIF1/IF1) is a mitochondrial inner-membrane protein conserved among eukaryotes that acts as the physiological inhibitor of the F1Fo‑ATP synthase, linking cellular energy status and respiratory chain activity to ATP preservation, mitochondrial membrane potential, and downstream signaling responses. The mature IF1 protein comprises an N‑terminal mitochondrial targeting sequence, a helical inhibitory region that interacts with the catalytic interface of the F1 sector, and a C‑terminal segment that supports oligomerization; its inhibitory activity is modulated by pH-dependent conformational changes and reversible oligomer formation, which alter its binding affinity for ATP synthase. During severe mitochondrial depolarization or loss of the proton motive force, IF1 binds to the F1 catalytic head, inhibiting the reverse, ATP-hydrolyzing action of ATP synthase, thereby preventing ATP depletion and contributing to the maintenance of a minimal mitochondrial membrane potential that supports cell survival during acute energy stress. IF1 also promotes assembly of ATP synthase dimers into oligomeric structures along mitochondrial cristae ridges, a configuration that lowers catalytic turnover, modifies proton flux, and preserves cristae ultrastructure, connecting IF1 to both the structural organization and the catalytic regulation of the oxidative phosphorylation machinery. Tissue-specific analyses reveal elevated IF1 levels in mitochondria-rich organs such as heart, liver, and brain, where its modulation of ATP synthase inhibition influences baseline oxidative phosphorylation rates, reactive oxygen species production, and the metabolic balance between oxidative phosphorylation and glycolysis. In cancer, IF1 is frequently overexpressed and is associated with a metabolic shift toward aerobic glycolysis: ATP synthase inhibition by IF1 reduces oxidative phosphorylation capacity, increases reliance on glycolytic ATP production, and activates retrograde signaling pathways based on changes in mitochondrial membrane potential and reactive oxygen species, supporting cell proliferation, survival under hypoxic or anoxic conditions, and, in certain contexts, an anti-metastatic phenotype. In the nervous system, IF1 expression and activity contribute to neuronal resilience, as experimental upregulation of IF1 protects dopaminergic neurons from mitochondrial toxins by restricting ATP hydrolysis, preserving mitochondrial integrity, and reducing apoptotic cell loss, indicating a neuroprotective function when respiratory chain integrity is compromised.

References
https://pubmed.ncbi.nlm.nih.gov/35620611/ https://pubmed.ncbi.nlm.nih.gov/37568591/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%